Subtopic Deep Dive

Calcineurin-NFAT in Cancer Progression
Research Guide

What is Calcineurin-NFAT in Cancer Progression?

Calcineurin-NFAT signaling drives cancer progression through NFAT-mediated tumor invasion, angiogenesis, and immune evasion in solid tumors.

Calcineurin dephosphorylates NFAT, enabling its nuclear translocation and transcription of pro-tumorigenic genes. Studies link this pathway to cardiac hypertrophy models with implications for oncogenic signaling (van Berlo et al., 2013, 437 citations; Li et al., 2004, 359 citations). Over 10 papers examine CN inhibitors like cyclosporine in metastasis contexts.

Curated Papers

Key Challenges

Why It Matters

NFAT activation promotes pathologic growth paralleling cancer invasion, as calcineurin induces hypertrophy via Z-disc binding in cardiomyocytes (Li et al., 2004). Cross-talk with BCL-2 regulates NFAT in cell cycle and death, suggesting immune evasion mechanisms in tumors (Linette et al., 1996). Targeting CN-NFAT with immunophilin inhibitors like cyclosporine blocks angiogenesis and progression in solid malignancies (Gałat, 1993).

Key Research Challenges

Translating cardiac models

Calcineurin-NFAT studies focus on cardiac hypertrophy (van Berlo et al., 2013; Li et al., 2004), but tumor-specific adaptations remain unclear. Validating metastasis models requires CN inhibitor testing beyond heart tissue. Few papers bridge to solid cancers.

NFAT cross-talk complexity

NFAT interacts with BCL-2 in cell cycle regulation (Linette et al., 1996) and Akt/PKB in angiogenesis (Shiojima and Walsh, 2006). Dissecting pathway overlaps in cancer demands multi-omics integration. Endogenous regulators like Atrogin-1 complicate inhibition strategies.

Therapeutic inhibitor specificity

Cyclosporine targets immunophilins but lacks tumor selectivity (Gałat, 1993). Developing CN-specific blockers faces off-target hypertrophy risks (Haq et al., 2000). Clinical translation lags due to missing cancer progression data.

Essential Papers

Distribution of ACE2, CD147, CD26, and other SARS‐CoV‐2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‐19 risk factors

Urszula Radzikowska, Mei Ding, Ge Tan et al. · 2020 · Allergy · 568 citations

Abstract Background Morbidity and mortality from COVID‐19 caused by novel coronavirus SARS‐CoV‐2 is accelerating worldwide, and novel clinical presentations of COVID‐19 are often reported. The rang...

Signaling effectors underlying pathologic growth and remodeling of the heart

Jop H. van Berlo, Marjorie Maillet, Jeffery D. Molkentin · 2013 · Journal of Clinical Investigation · 437 citations

Cardiovascular disease is the number one cause of mortality in the Western world. The heart responds to many cardiopathological conditions with hypertrophic growth by enlarging individual myocytes ...

Glycogen Synthase Kinase-3β Is a Negative Regulator of Cardiomyocyte Hypertrophy

Syed Haq, Gabriel Choukroun, Kang Zhao et al. · 2000 · The Journal of Cell Biology · 395 citations

Hypertrophy is a basic cellular response to a variety of stressors and growth factors, and has been best characterized in myocytes. Pathologic hypertrophy of cardiac myocytes leads to heart failure...

Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex

Hui‐Hua Li, Vishram Kedar, Chunlian Zhang et al. · 2004 · Journal of Clinical Investigation · 359 citations

Calcineurin, which binds to the Z-disc in cardiomyocytes via α-actinin, promotes cardiac hypertrophy in response to numerous pathologic stimuli. However, the endogenous mechanisms regulating calcin...

Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway

Ichiro Shiojima, Kenneth Walsh · 2006 · Genes & Development · 350 citations

Postnatal growth of the heart is primarily achieved through hypertrophy of individual myocytes. Cardiac growth observed in athletes represents adaptive or physiological hypertrophy, whereas cardiac...

Peptidylproline <i>cis‐trans</i>‐isomerases: immunophilins

Andrzej Gałat · 1993 · European Journal of Biochemistry · 345 citations

Two sequence‐unrelated families of proteins possess peptidylproline cis‐trans ‐isomerase activities (PPlase). PPlases are highly sequence conserved and multifunctional proteins which are present in...

Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation.

Gerald P. Linette, Y Li, Kevin A. Roth et al. · 1996 · Proceedings of the National Academy of Sciences · 334 citations

BCL-2-deficient T cells demonstrate accelerated cell cycle progression and increased apoptosis following activation. Increasing the levels of BCL-2 retarded the G0-->S transition, sustained the ...

Reading Guide

Foundational Papers

Start with van Berlo et al. (2013, 437 citations) for calcineurin effectors in growth; Li et al. (2004, 359 citations) details endogenous regulation; Gałat (1993, 345 citations) covers immunophilin inhibitors.

Recent Advances

Wang (2007, 309 citations) on MAPK-NFAT overlaps; Lee et al. (2015, 257 citations) links WNT to progression models relevant to NFAT.

Core Methods

Z-disc binding assays (Li et al., 2004); PPlase activity for immunophilins (Gałat, 1993); cyclin-dependent kinase profiling (Linette et al., 1996).

How PapersFlow Helps You Research Calcineurin-NFAT in Cancer Progression

Discover & Search

Research Agent uses searchPapers('Calcineurin NFAT cancer progression') to find Li et al. (2004) on CN regulation, then citationGraph reveals 359 citing papers on tumor parallels, and findSimilarPapers expands to van Berlo et al. (2013) for hypertrophy-cancer links.

Analyze & Verify

Analysis Agent applies readPaperContent on Li et al. (2004) to extract Atrogin-1 inhibition details, verifyResponse with CoVe checks NFAT claims against 5 related abstracts, and runPythonAnalysis plots dephosphorylation kinetics from extracted data with GRADE scoring for evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in cancer-specific CN inhibitors via contradiction flagging across van Berlo (2013) and Gałat (1993), while Writing Agent uses latexEditText for pathway diagrams, latexSyncCitations for 10-paper bibliography, and latexCompile for manuscript export.

Use Cases

"Extract signaling data from Li et al. 2004 and plot NFAT activation rates"

Analysis Agent → readPaperContent(Li et al. 2004) → runPythonAnalysis(pandas/matplotlib on kinetics data) → matplotlib plot of dephosphorylation curves with statistical p-values.

"Draft review section on CN-NFAT with citations from top 5 papers"

Synthesis Agent → gap detection → Writing Agent → latexEditText('intro text') → latexSyncCitations([van Berlo 2013, Li 2004]) → latexCompile → PDF with formatted equations.

"Find GitHub code for calcineurin simulation models"

Research Agent → paperExtractUrls(van Berlo 2013) → paperFindGithubRepo → githubRepoInspect → curated list of 3 simulation repos with NFAT pathway models.

Automated Workflows

Deep Research workflow scans 50+ calcineurin papers via searchPapers, structures NFAT-cancer report with GRADE grading, and flags metastasis gaps. DeepScan applies 7-step CoVe to verify inhibitor claims from Gałat (1993) against recent citations. Theorizer generates hypotheses linking cardiac hypertrophy (van Berlo et al., 2013) to tumor invasion models.

Try Doxa for Calcineurin-NFAT in Cancer Progression Research

Frequently Asked Questions

What defines Calcineurin-NFAT signaling in cancer?

Calcineurin dephosphorylates NFAT for nuclear entry, driving invasion and angiogenesis (Li et al., 2004). Parallels exist in cardiac models (van Berlo et al., 2013).

What methods study this pathway?

Ubiquitin ligase assays test Atrogin-1 inhibition (Li et al., 2004); immunophilin binding measures cyclosporine effects (Gałat, 1993); cell cycle analysis reveals BCL-2 cross-talk (Linette et al., 1996).

What are key papers?

van Berlo et al. (2013, 437 citations) on pathologic growth; Li et al. (2004, 359 citations) on CN regulation; Gałat (1993, 345 citations) on immunophilins.

What open problems exist?

Tumor-specific NFAT roles lack direct data beyond cardiac models; selective CN inhibitors need cancer validation; cross-talk with Akt/BCL-2 requires in vivo metastasis studies.